DOI: 10.36347/sjams.2022.v10i05.028

Pages: 846-851

Background: Management of moderate persistent asthma is very crucial among the patients. Objective: The purpose of the present study was to see the efficacy and safety of hydrofluoroalkane beclomethasone dipropionate (HFA-BDP) by comparing the chlorofluorocarbon beclomethasone dipropionate (CFC-BDP) for the treatment of moderate persistent asthma. Methodology: This randomized clinical trial was carried out at the outpatient department (OPD) of National Institute of diseases of the Chest and Hospital (NIDCH), Mohakhali, Dhaka from July 2010 to June 2011 for one year. All men and women aged from 18 to 65 years suffering from moderate persistent bronchial asthma attending the OPD of NIDCH, Mohakhali, and Dhaka during the specified period were enrolled after fulfilling the selection criteria. Eligible patients were randomized by odd or even identification numbers divided into group A and group B and they received coded HFA-BDP (400 µg/day) or CFC-BDP (1000 µg/day) respectively for 12 weeks. The patients were evaluated at 4th, 8th and 12th weeks after starting the treatment. The outcome parameters were spirometry (FEV1 and PEFR). Results: All 97 patients were divided into two groups (A & B) by odd or even number. Group A consisted of 49 patients who were treated with HFA-BDP in an amount of 400µg/day and group B consisted of the remaining 48 patients who were treated with CFC-BDP in an amount of 1000µg/day. The mean age of HFA and CFC inhaler group is 27.49 ± 7.04 and 27.98 ± 7.86 (p=0.747) respectively. Baseline PEFR was 65.45 ± 2.26 and 65.00 ± 2.38 in HFA and CFC inhaler group respectively (p=0.343). PEFR at 1st follow up (p<0.001), at 2nd follow up (p<0.001) and at 3rd follow up (p<0.001) in HFA and CFC inhaler group were significant. PEFR difference between baseline and 1st follow up, 1st and 2nd follow up, and 2nd and 3rd follow up found in HFA and CFC inhaler group respectively were statistically significant (p<0.001). FEV1 at 1st follow up (p<0.001),..